Aerie reports positive phase 3 results for netarsudil 0.02% vs ripasudil 0.4% in lowering IOP


Aerie Pharmaceuticals announced Tuesday positive topline results for the phase 3 trial evaluating netarsudil 0.02% versus ripasudil 0.4% for the treatment of open-angle glaucoma and elevated IOP.

Aerie Pharmaceuticals announced Tuesday positive topline results for the Japan-based, phase 3 trial evaluating netarsudil ophthalmic solution 0.02% (netarsudil 0.02%) versus ripasudil hydrochloride hydrate ophthalmic solution 0.4% (ripasudil 0.4%).

As Rho kinase (ROCK) inhibitors, netarsudil 0.02% — known as Rhopressa® in the U.S. — and ripasudil 0.4% — known as Rhokiinsa® in the EU — are intended to treat open-angle glaucoma (OAG) and elevated intraocular pressure (IOP), according to a company news release.

The clinical trial included a single-masked comparison of netarsudil 0.02% dosed once daily versus ripasudil 0.4% dosed twice daily in 245 participants for four weeks.

Of the 245 patients, 122 received netarsudil 0.02% while 123 received ripasudil 0.4%. In total, 238 participants completed the study.

Trial results revealed that netarsudil 0.02% once daily was superior to ripasudil 0.4% daily in lowering at week 4 (p<0.0001), the primary endpoint for the study, the company reported.

The baseline mean diurnal IOP was 20.5 and 20.8 mmHg in the netarsudil 0.02% and ripasudil 0.4% arm, respectively.

Additionally, the mean diurnal IOP was significantly lower (16.0 mmHg) in the netarsudil 0.02% group compared to the ripasudil 0.4% group (17.7 mmHg, p<0.0001), the company stated.

At four weeks, netarsudil 0.02% reduced mean diurnal IOP by 4.7 mmHg (22.6%) from baseline compared to 3.0 mmHg (14.3%) with ripasudil 0.4% (p<0.0001), according to the company.

Aerie reported that both medications were well-tolerated, with the most common treatment emergent adverse event being conjunctival hyperemia (54.9% of subjects with netarsudil 0.02%; 62.6% of subjects with ripasudil 0.4%).

The trial was conducted in alignment with Japan’s Medical Devices Agency (PMDA) in anticipation of a potential regulatory submission of netarsudil 0.02% in Japan.

We believe that the statistically superior IOP-lowering of netarsudil versus the comparator in our study may suggest a very bright future for our product in Japan, a market where the comparator product is the only rho-kinase inhibitor commercially available,” said Benjamin F. McGraw, III, PharmD, Aerie’s interim executive chairman. “The IOP-lowering with netarsudil was consistent with that seen in the previous Phase 2 study conducted in Japan as well as in our ROCKET and MERCURY studies conducted in the United States for Rhopressa® and Rocklatan®, respectively.”